Results 61 to 70 of about 9,435,635 (153)

Modified Adeno-associated virus (AAV) particles for gene therapy

open access: yes, 2019
The present invention relates to improved adeno-associated virus (AAV) particles for gene delivery and gene therapy. Provided are adeno associated virus (AAV) particles that comprise a modified capsid. The present invention further relates to methods for
Heppenstall, P.   +3 more
core   +1 more source

Association between adeno‐associated virus genomic titers and intracellular plasmid levels

open access: yesEngineering Reports
The recombinant adeno‐associated viral (rAAV) vector is one of the most effective viral vectors in gene therapy because of its low immunogenicity, high transduction efficiency, broad tissue specificity, and long‐term transgene expression ability. HEK293T
Kyoko Masumi‐Koizumi   +4 more
doaj   +1 more source

Onset of experimental severe cardiac fibrosis is mediated by overexpression of angiotensin-converting enzyme 2 [PDF]

open access: yes, 2009
Angiotensin-converting enzyme (ACE) 2 is a recently identified homologue of ACE. There is great interest in the therapeutic benefit for ACE2 overexpression in the heart.
Smith, Godfrey   +12 more
core   +1 more source

Comprehensive mutagenesis maps the effect of all single-codon mutations in the AAV2 rep gene on AAV production

open access: yeseLife
Recombinant adeno-associated viruses (rAAVs) are the predominant gene therapy vector. Several rAAV vectored therapies have achieved regulatory approval, but production of sufficient rAAV quantities remains difficult.
Nina K Jain   +2 more
doaj   +1 more source

Capsid-specific removal of circulating antibodies to adeno-associated virus vectors

open access: yes, 2020
International audienceNeutralizing antibodies directed against adeno-associated virus (AAV) are commonly found in humans. In seropositive subjects, vector administration is not feasible as antibodies neutralize AAV vectors even at low titers ...
Deschamps, Jack-Yves   +17 more
core   +1 more source

Glycosylation of recombinant adeno-associated virus serotype 6

open access: yesMolecular Therapy: Methods & Clinical Development
Glycosylation of biopharmaceuticals can affect their safety and efficacy. Glycans can occur on recombinant adeno-associated viruses (rAAVs) that are used for gene therapy; however, the types of glycans that attach to rAAVs are controversial.
Yuki Yamaguchi   +18 more
doaj   +1 more source

Gene Delivery to Nonhuman Primate Preimplantation Embryos Using Recombinant Adeno‐Associated Virus

open access: yesAdvanced Science, 2019
Delivery of genome editing tools to mammalian zygotes has revolutionized animal modeling. However, the mechanical delivery method to introduce genes and proteins to zygotes remains a challenge for some animal species that are important in biomedical ...
Dan Wang   +9 more
doaj   +1 more source

Orthopaedic gene therapy using recombinant adeno-associated virus vectors

open access: yes, 2011
Use of recombinant adeno-associated virus (rAAV) vectors is increasingly gaining popularity in gene therapy because of their desirable properties, including lack of pathogenicity, efficient transduction of dividing and non-dividing cells, and sustained ...
Ke, J   +5 more
core   +1 more source

Adeno-associated virus (AAV)-mediated suppression of Ca2+/calmodulin kinase IV activity in the nucleus accumbens modulates emotional behaviour in mice-1

open access: yes, 2011
Copyright information:Taken from "Adeno-associated virus (AAV)-mediated suppression of Ca2+/calmodulin kinase IV activity in the nucleus accumbens modulates emotional behaviour in mice"http://www.biomedcentral.com/1471-2202/8/105BMC Neuroscience 2007;8():
Hilmar Bading (78535)   +4 more
core   +1 more source

Stable Producer Cell Lines for Adeno-Associated Virus (AAV) Assembly

open access: yes, 2010
INTRODUCTIONStable producer cell lines containing both the rep and cap genes and recombinant adeno-associated virus (rAAV) vectors can be infected with a helper virus to provide reliable and efficient production of rAAV stocks.
Anna Salvetti, Gilliane Chadeuf
core   +1 more source

Home - About - Disclaimer - Privacy